Damora Therapeutics, Inc. Ordinary Shares
DMRA
12 hedge funds and large institutions have $633K invested in Damora Therapeutics, Inc. Ordinary Shares in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
40% more capital invested
Capital invested by funds: $451K → $633K (+$182K)
33% more funds holding
Funds holding: 9 → 12 (+3)
2.81% more ownership
Funds ownership: 10.04% → 12.85% (+2.8%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$91.3K |
| 2 |
Two Sigma Investments
New York
|
+$68.7K |
| 3 |
VF
Virtu Financial
New York
|
+$44.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$17.9K |
| 5 |
Renaissance Technologies
New York
|
+$1.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$45.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$45.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.63K |
| 4 |
Barclays
London,
United Kingdom
|
-$152 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NHAS
1
Novo Holdings A/S
Hellerup,
Denmark
| $322K | -$45.2K | -13,334 | -13% |
|
|
CCM
2
Connective Capital Management
Palo Alto,
California
| $100K | +$91.3K | +26,956 | New |
|
|
3
Two Sigma Investments
New York
| $75.5K | +$68.7K | +20,296 | New |
|
|
4
Renaissance Technologies
New York
| $56K | +$1.69K | +500 | +3% |
|
|
VF
5
Virtu Financial
New York
| $49K | +$44.5K | +13,128 | New |
|
|
6
Bank of America
Charlotte,
North Carolina
| $24.2K | +$17.9K | +5,272 | +429% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $5.31K | +$1.64K | +485 | +51% |
|
8
BlackRock
New York
| $372 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $220 | -$7.63K | -2,254 | -97% |
|
|
10
Barclays
London,
United Kingdom
| $205 | -$152 | -45 | -45% |
|
11
Citigroup
New York
| $160 | +$146 | +43 | New |
|
|
SS
12
SBI Securities
Tokyo,
Japan
| $67 | – | – | – |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$45.2K | -13,602 | Closed |
|
DMRA Hedge Fund Activity: Q3 2025 in Review
12 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q3 2025, worth a combined $633K — up 40% from $451K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMRA positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $91.3K. The largest seller was Novo Holdings A/S, cutting an estimated $45.2K.
- 12 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q3 2025, up from 9 in Q2 2025.
- Funds reported $633K of Damora Therapeutics, Inc. Ordinary Shares stock for Q3 2025, up 40% quarter-over-quarter.
- 4 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q3 2025 and 1 closed out, a net change of +3 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q3 2025 was Connective Capital Management, an estimated $91.3K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q3 2025 was Novo Holdings A/S, an estimated $45.2K sold.
Based on aggregated 13F filings for Q3 2025.